Ionis Pharmaceuticals (IONS) Expected to Announce Quarterly Earnings on Wednesday

Ionis Pharmaceuticals (NASDAQ:IONS) is expected to be posting its quarterly earnings results before the market opens on Wednesday, February 19th. Analysts expect Ionis Pharmaceuticals to post earnings of ($1.09) per share and revenue of $140.97 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Ionis Pharmaceuticals Price Performance

NASDAQ IONS opened at $31.58 on Wednesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The firm has a market capitalization of $4.99 billion, a PE ratio of -12.94 and a beta of 0.34. The company’s 50 day simple moving average is $34.62 and its 200 day simple moving average is $39.22. Ionis Pharmaceuticals has a 12 month low of $30.90 and a 12 month high of $52.34.

Analysts Set New Price Targets

Several research firms have weighed in on IONS. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Wednesday, January 15th. StockNews.com lowered shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Wells Fargo & Company dropped their price target on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, November 7th. William Blair reissued an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Friday, December 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, CEO Brett P. Monia sold 33,445 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $32.63, for a total value of $1,091,310.35. Following the transaction, the chief executive officer now owns 207,396 shares of the company’s stock, valued at approximately $6,767,331.48. The trade was a 13.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Eric Swayze sold 7,154 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $32.84, for a total transaction of $234,937.36. Following the sale, the executive vice president now directly owns 45,670 shares of the company’s stock, valued at $1,499,802.80. This represents a 13.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 110,609 shares of company stock valued at $3,564,867 in the last 90 days. 2.71% of the stock is owned by insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.